|DB00170||Menadione||The primary known function of vitamin K is to assist in the normal clotting of blood, but it may also play a role in normal bone calcification.|
|DB00302||Tranexamic acid||For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.|
|DB00513||Aminocaproic Acid||For use in the treatment of excessive postoperative bleeding.|
|DB01022||Phylloquinone||For the treatment of haemorrhagic conditions in infants, antidote for coumarin anticoagulants in hypoprothrombinaemia.|
|DB06692||Aprotinin||For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.|
|DB09005||Batroxobin||No approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously.|
|DB09012||Carbazochrome||Indicated for capillary and parenchymal hemorrhage (trauma, tonsillectomy, during surgery), intestinal bleeding, and thrombocytopenic purpura.|
|DB11300||Thrombin||Bovine thrombin is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (like suture, ligature, or cautery) is ineffective or impractical [FDA Label]. Additionally, topical bovine thrombin can also be used in combination with an absorbable gelatin sponge, USP [FDA Label].|
|DB13570||Oxidized cellulose||Not Available|
|DB13372||Calcium alginate||Not Available|
|DB00025||Antihemophilic factor, human recombinant||For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.|
|DB00036||Coagulation factor VIIa Recombinant Human||For treatment of hemorrhagic complications in hemophilia A and B|
|DB00100||Coagulation Factor IX (Recombinant)||For treatment of hemophilia (Christmas disease).|
|DB09222||Fibrinogen Human||For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.|
|DB09310||Catridecacog||For routine prophylaxis of bleeding in patients with congenital factor XIII A-Subunit deficiency.|
|DB11606||Susoctocog alfa||Indicated for the treatment of bleeding episodes in adults with acquired hemophilia A.|
|DB13151||Anti-inhibitor coagulant complex||For use in the control of bleeding episodes, perioperative management, and routine prophylaxis against bleeding episodes in hemophilia A and B patients with inhibitors [FDA Label]. It is not indicated in the absence of factor VIII or IX inhibitors.|
|DB00035||Desmopressin||- Indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void (intranasal).
- Indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral).
- Indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% or mild to moderate classic von Willebrand's Disease (Type I) with factor VIII levels greater than 5% during surgical procedures and postoperatively to maintain hemostasis (parenteral).|
|DB00067||Vasopressin||For the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding|
|DB01942||Formic acid||Not Available|
|DB13075||Menaquinone 7||Not Available|
|DB13529||Dobesilic acid||Not Available|
|DB13885||Ferric subsulfate||Not Available|
|DB13909||Bismuth subgallate||The most common medical purpose for which bismuth subgallate is currently and formally indicated for is the use as a non-prescription internal deodorant product for the purpose of deodorizing flatulence and stools [L2309, L2312, A32566].
Additionally, there are also various non-prescription (over the counter) bismuth subgallate based wound healing products as well as ongoing studies into whether or not the substance can be utilized as a legitimate hemostatic agent - usually for soft tissue surgery in otorhinolaryngology and/or dermatologic settings [A32567, A32568, A32569, A32570].
Moreover, in the past bismuth subgallate may have seen some use as a treatment for Helicobacter pylori infection [A32571]. In contrast, contemporary first-line therapies generally involve proton pump inhibitor and antibiotic combination therapies that generally achieve high rates of pathogen eradication, ease of administration, and patient compliance.|
|DB00058||Alpha-1-proteinase inhibitor||For chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.|
|DB05332||Romiplostim||Treatment of chronic immune thrombocytopenic purpura. |
|DB06210||Eltrombopag||Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction. |
|DB13133||Von Willebrand Factor Human||The vWF and Factor VIII complex is indicated for the prevention of excessive bleeding during and after minor and major surgery in adult and pediatric von Willebrand disease patients. It is also indicated for the on-demand treatment and control of bleeding episodes.[L1880] The von Willebrand disease is an inherited disorder characterized by the deficiency or misfunction of the von Willebrand factor (vWF). Due to this deficiency, the blood cannot clot properly and the patients that present this disease are prone to prolonged or excessive bleeding. There are three types of this disease, and type 3 is an autosomal recessive inherited disorder marked by very low or absent levels of vWF.[L1867]|
|DB13148||Coagulation factor X human||Indicated in adults and children (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes, or for perioperative management of bleeding in patients with mild hereditary Factor X deficiency [FDA Label]. |
|DB13192||Antihemophilic factor human||The human antihemophilic factor is indicated for the cases of hemophilia A, also known as classical hemophilia for the prevention and control of hemorrhagic episodes.[L1055] If surgery is needed in patients with hemophilia A there is a need of correction of the clotting abnormality. In this cases, the human antihemophilic factor may be administered followed by intermittent maintenance doses.[L1053] The hemophilia A is characterized by the deficiency of the coagulation factor VIII that results in prolonged blood flow after injury or surgery as well as recurrent bleeding.[T56]|
|DB13244||Aminomethylbenzoic acid||Not Available|
|DB13621||Tetragalacturonic acid hydroxymethylester||Not Available|
|DB09109||Turoctocog alfa||Turoctocog alfa is indicated for the treatment and prophylaxis of bleedings in patients presenting hemophilia A.[L1105] The treatment with turoctocog alfa is related with its use to control bleeding episodes or as a perioperative management.[L1106] Hemophilia A is a hereditary hemorrhagic disorder generated by the congenital deficit of the coagulation factor VIII. This disease is manifested as excessive spontaneous or trauma-driven bleeding. The coagulation factor VIII is a robust initiator of thrombin which is later required for the generation of fibrin to form a platelet plug and its gene is expressed in the X chromosome.[A31505]|
|DB09329||Antihemophilic Factor (Recombinant), PEGylated||For the management of hemophilia A (congenital factor VIII deficiency) [FDA label], [A32064].
This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency). It is also used for on-demand treatment and control of bleeding and routine prophylaxis of bleeding episodes. It is not indicated for the treatment of von Willebrand disease [FDA label].|
|DB11572||Thrombin alfa||Indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical in adults and pediatric populations greater than or equal to one month of age [FDA Label].
Additionally, thrombin alfa can be used in conjunction with an absorbable gelatin sponge, USP [FDA Label].|
|DB11607||Efmoroctocog alfa||Indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) [FDA Label].|
|DB11608||Eftrenonacog alfa||Indicated for the treatment and prophylaxis of bleeding in patients of all age with haemophilia B (congenital factor IX deficiency).|
|DB12909||Factor XIII (human)||Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency [FDA Label].|
|DB13152||Coagulation Factor IX Human||Factor IX is used to treat Christmas disease. Factor IX deficiency is treated by injection factor IX produced from human plasma. Tranexamic acid may be of value in patients undergoing surgery who have inherited factor IX deficiency in order to reduce the perioperative risk of bleeding.|
|DB13884||Albutrepenonacog alfa||Under the EMA and FDA, rIX-RFP is indicated in the treatment of hemophilia B.[L2306] For Health Canada, rIX-FRP is also indicated to prevent or reduce bleeding episodes.[L2305]
Hemophilia B is the second most common type of hemophilia. It is a rare inherited bleeding disorder caused by reduced or absent levels of factor IX (FIX). The FIX is a vitamin K-dependent plasma protease that when activated is involved in the blood coagulation cascade.[A32551] The hemophilia B is caused by mutations in the _FIX_ gene which can cause different phenotypes. The severe form is characterized by the presence of spontaneous and recurring bleeds into the joints and muscles and excessive bleeding after trauma or surgery.[A32552]|
|DB13933||Nonacog beta pegol||Nonacog beta pegol is indicated for the use in adults and children with hemophilia B for control and prevention of bleeding episodes, routine prophylaxis and perioperative management.[L1100] In the EMA approval, it is also indicated for on-demand treatment of bleeding episodes.[L1099] Hemophilia B is characterized by a deficiency in the coagulation factor IX which results in prolonged oozing after injuries and delayed or recurring bleeding prior wound healing. Hemophilia B patients present more frequent bleeding episodes during childhood and adolescence than in adulthood.[T56]|
|DB13968||Plasma protein fraction (human)||PPFh is used as a replacement therapy in patients with complex deficiencies of coagulation factors such as coagulopathy. It is also used as a substitution therapy in emergency cases of factor deficiencies, for rapid reversal of the effects of oral anticoagulants or in dangerous hemorrhages during fibrinolytic therapy. PPFh can be used in therapeutic plasma exchange procedures including thrombotic thrombocytopenic purpura.[L2264]
PPFh can be used in the treatment of shock where there is a predominant loss of plasma fluids and not red blood cells.[L2261]|
|DB13998||Lonoctocog alfa||For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.|
|DB13999||Moroctocog alfa||Moroctocog Alfa is approved by Health Canada for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).
Moroctocog Alfa is also approved by the European Medicines Agency for the treatment and prophylaxis of bleeding in patients with Haemophilia A (congenital factor VIII deficiency).|
|DB00668||Epinephrine||Epinephrine injection is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. Injectable epinephrine is intended for immediate/urgent administration in patients, who are found to be at increased risk for anaphylaxis, including individuals with a history of anaphylaxis. Selection of the appropriate dosage strength is determined according to body weight [FDA label].
Epinephrine's cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock [F1247].
Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics [F1247].
In addition to the above, epinephrine is used as an over the counter (OTC) agent for the intermittent symptoms of asthma, such as wheezing, tightness of chest and shortness of breath [F2131]. It is also used for the maintenance of mydriasis during intraocular surgery [L4825].|
|DB14492||Potassium triiodide||Not Available|
|DB14738||Turoctocog alfa pegol||Turoctocog alfa pegol (N8-GP) is indicated for use in adults and children of all ages with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis in reducing the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes, and the perioperative management of bleeding [F3649].|
|DB11995||Avatrombopag||Indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure [FDA label].|
|DB12010||Fostamatinib||Fostamatinib is indicated for use in the treatment of chronic immune thrombocytopenia (ITP) in patients who have had insufficient response to previous therapy [FDA Label].|
|DB13125||Lusutrombopag||Lusutrombopag is indicated for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.|
|DB13923||Emicizumab||The main function of Emicizumab is the prevention of bleeding episodes. Thus, Emicizumab is approved for the routine prophylaxis to prevent or reduce the frequency of bleeding episodes of adult and pediatric patients with hemophilia A with or without Factor VIII inhibitors.[L4657]
Hemophilia A is a deficiency of coagulation Factor VIII which causes a serious bleeding disorder. The standard treatment is done with the administration of recombinant or serum-deriver Factor VIII which induces the formation of anti-factor VIII alloantibodies (Factor VIII inhibitors) and renders the standard treatment ineffective.[A31286]|
|DB14936||Menaquinone 6||Not Available|